Skip to main content

A breakthrough in Renal Cell Carcinoma: Personalized RCC-Test

Objective

In oncology today, only 10 to 15% of patients respond strongly to therapeutic treatments. Metastatic renal cell cancer (mRCC) is no exception. It is one of the most treatment-resistant malignancies. 30% of patients are diagnosed with a metastatic disease. In such cases, the only solution is a radical surgical resection of the tumor, followed by the necessary therapies. About 80% of cases fail to respond to current therapeutic agents.
New protocols with combined immuno- and targeted therapies have shown highly promising results. However, it is extremely difficult to interpret these results. Each patient is different and defining the appropriate set of therapies for mRCC has become increasingly complex.
RCC-TEST is a new in vitro diagnostic tool, which will revolutionize the RCC post-surgical treatment. It will allow for rapid and cost-effective testing of a therapy’s effectiveness for each patient, before starting complex and expensive therapeutic protocols. Clinicians will be able to prescribe personalized treatments and to prolong patients’ lives, thereby reducing medical expenses.
The new test is based on the ICELLTIS breakthrough 3D multicellular tumor spheroids, which are specific to RCC. For the first time, these spheroids are composed of the patient’s own tumor and immune cells, which are key determinants for the efficient in vitro investigation of responses and resistance of tumor cells to medical drugs.
During Phase 1, ICELLTIS will scale-up RCC-TEST in order to prepare and be ready for further European clinical trials. A market study will be realized in order to investigate new international market opportunities and to challenge different commercial strategies. The main deliverable will be an updated business plan.
ICELLTIS sees a huge business opportunity to further exploit their know-how in 3D (spheroid) tumor cell culture models. This feasibility study is an essential first step before the routine clinical practice and industrial production.

Field of science

  • /medical and health sciences/basic medicine/immunology/immunotherapy
  • /medical and health sciences/clinical medicine/cancer

Call for proposal

H2020-SMEINST-1-2015
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

ICELLTIS
Address
436 Rue Pierre Et Marie Curie Immeuble Biostep
31670 Labege
France
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000